|1.||Weissmann, Norbert: 21 articles (09/2014 - 01/2004)|
|2.||Seeger, Werner: 20 articles (07/2014 - 01/2004)|
|3.||Grimminger, Friedrich: 17 articles (09/2013 - 01/2004)|
|4.||Humbert, Marc: 12 articles (10/2015 - 12/2009)|
|5.||Schermuly, Ralph T: 12 articles (09/2014 - 01/2004)|
|6.||Schermuly, Ralph Theo: 11 articles (09/2013 - 04/2004)|
|7.||Eddahibi, Saadia: 10 articles (02/2015 - 05/2003)|
|8.||Kadowitz, Philip J: 10 articles (10/2014 - 02/2007)|
|9.||Ghofrani, Hossein Ardeschir: 10 articles (09/2013 - 04/2004)|
|10.||Adnot, Serge: 9 articles (03/2015 - 05/2003)|
|1.||Pulmonary Hypertension (Ayerza Syndrome)
11/01/2006 - "This study showed that increased expression of PCI in the lung is protective against monocrotaline-induced pulmonary hypertension, suggesting a potential beneficial effect of PCI for the therapy of this disease."
01/01/2015 - "Salvia Miltiorrhiza Bge.f.alba Ameliorates the Progression of Monocrotaline-Induced Pulmonary Hypertension by Protecting Endothelial Injury in Rats."
10/15/2014 - "Intratracheal administration of cyclooxygenase-1-transduced adipose tissue-derived stem cells ameliorates monocrotaline-induced pulmonary hypertension in rats."
09/01/2009 - "We tested whether CBDL ameliorates monocrotaline (MCT)-induced pulmonary hypertension (PH) in rats. "
12/01/2004 - "We investigated whether CNP ameliorates monocrotaline (MCT)-induced pulmonary hypertension in rats. "
08/15/2013 - "We used loss and gain of function in vivo studies to establish the role and determine the therapeutic effect of endothelial IDO in hypoxia-induced PH in mice and monocrotaline-induced PH in rats. "
06/01/2012 - "In both hypoxia and monocrotaline-induced PAH rat models, which display reduced levels of bmpr2 transcripts, this study further indicates that the TGFβ-MAPK axis is activated in lungs following elevation of both expression and phosphorylation of the TAK1 protein. "
07/01/2010 - "The present study found that Smurf1 was significantly elevated in pulmonary arteries of monocrotaline and hypoxia-induced PAH rats. "
05/01/2004 - "The present study was carried out to explore if there are temporal alterations in HIF-1alpha levels during prolonged hypoxia and after monocrotaline (MCT) treatment. "
01/01/1996 - "This study was performed to test whether monocrotaline (MCT)-induced early airway dysfunction and gas exchange abnormalities result in arterial hypoxemia. "
|3.||Right Ventricular Hypertrophy
01/10/2015 - "Intravenous administration of BPS-NP (once per week, 20μg/kg) protected against monocrotaline-induced pulmonary arterial remodeling and right ventricular hypertrophy. "
03/01/2013 - "The mean pulmonary arterial pressure, right ventricular hypertrophy, pulmonary vascular remodeling index, content of apelin protein in lung tissue of monocrotaline group were higher than those in control group. "
02/01/2013 - "In vivo, RAGE inhibition in monocrotaline- and Sugen-induced PAH demonstrates therapeutic effects characterized by PA pressure and right ventricular hypertrophy decrease (control rats have an mPAP around 15 mm Hg, PAH rats have an mPAP >40 mm Hg, and with RAGE inhibition, mPAP decreases to 20 and 28 mm Hg, respectively, in MCT and Sugen models). "
04/15/2012 - "Cardiac-specific genetic inhibition of nuclear factor-κB prevents right ventricular hypertrophy induced by monocrotaline."
04/01/2012 - "The pulmonary arterial pressure (PAP) started to increase at least 7 days after monocrotaline injection, and the rats developed severe PAH in 21 days with high PAP, right ventricular hypertrophy and neointimal formation. "
02/01/2010 - "The aim of the present study was to investigate the protective effects of RSV against monocrotaline (MCT)-induced right ventricular (RV) hypertrophy in rats. "
01/01/2015 - "In rats with monocrotaline-induced PAH, PTU therapy improved pulmonary arterial hypertrophy and hemodynamics. "
01/01/2016 - "This study aimed to evaluate the effects of rhNRG-1 in RV function and pulmonary vasculature in monocrotaline (MCT)-induced PAH and RV hypertrophy (RVH). "
07/01/1992 - "In the present study, we measured and characterized pulmonary artery (PA) elastolytic activity at time points before as well as coincident with the progression of medial hypertrophy in monocrotaline-injected adult male Sprague-Dawley rats. "
09/15/2015 - "Finally, we demonstrated that restoring the expression of miR-223 in lungs of rats with monocrotaline-induced PAH reversed established PAH and provided beneficial effects on vascular remodeling, pulmonary resistance, right ventricle hypertrophy, and survival. "
|5.||Cardiomegaly (Heart Hypertrophy)
03/22/2011 - "Chronic nebulization of PDE3/4 inhibitor significantly attenuated monocrotaline-induced hemodynamic, gas exchange abnormalities, vascular remodeling, and right heart hypertrophy. "
09/02/2005 - "Since mechanical stress plays an important role in transcriptional regulation of a gene involved in cardiac hypertrophy and remodeling, we generated left-sided or right-sided pressure-overload models by transverse aortic constriction (TAC) in ddY mice or by monocrotaline administration in Wistar rats, respectively. "
01/01/2005 - "Monocrotaline injection provoked severe PAH (right ventricular systolic pressure increased from 25.9 +/- 4.0 to 68.9 +/- 3.2 after 4 weeks and 74.9 +/- 5.1 mmHg after 6 weeks), cardiac output depression and right heart hypertrophy. "
04/30/2004 - "When chronically infused from days 14 to 28, both agents significantly attenuated all monocrotaline-induced hemodynamic and gas exchange abnormalities as well as right heart hypertrophy. "
12/01/1999 - "We also examined the modulation of these NPRs during cardiac hypertrophy induced by monocrotaline (MCT). "
|3.||Idiopathic pulmonary hypertension
|5.||fasudil (AT 877)
|8.||prostacyclin synthetase (prostacyclin synthase)
|10.||GTP Phosphohydrolases (GTPases)
|1.||Transplantation (Transplant Recipients)
|5.||Pneumonectomy (Lung Volume Reduction)